Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease

Glucagon-like peptide-1 (GLP-1) receptor agonist use is associated with reduced mortality and improved cardiovascular outcomes in the general population with diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used antidiabetic agents for patients with advanced-stage chronic kidney dise...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA network open 2022-03, Vol.5 (3), p.e221169-e221169
Hauptverfasser:	Chen, Jia-Jin, Wu, Chao-Yi, Jenq, Chang-Chyi, Lee, Tao-Han, Tsai, Chung-Ying, Tu, Hui-Tzu, Huang, Yu-Tung, Yen, Chieh-Li, Yen, Tzung-Hai, Chen, Yung-Chang, Tian, Ya-Chung, Yang, Chih-Wei, Yang, Huang-Yu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antidiabetics Cerebrovascular disease Cohort Studies Diabetes Diabetes and Endocrinology Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - metabolism Female GLP-1 receptor agonists Glucagon Glucagon-Like Peptide 1 - metabolism Glucagon-Like Peptide-1 Receptor - agonists Humans Hypoglycemic Agents - therapeutic use Kidney diseases Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - epidemiology Male Middle Aged Mortality Online Only Original Investigation Peptides Renal Insufficiency, Chronic Retrospective Studies Sepsis Sepsis - complications Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Taiwan - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!